title: Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function.
abstract: OBJECTIVE
  To determine the pharmacokinetics of oral flecainide acetate after single and multiple doses in patients with impaired renal function.
  
  
  METHODS
  Paired study of single followed by multiple oral doses.
  
  
  METHODS
  PATIENTS enrolled in a Veterans Administration Hospital renal subspecialty clinic and dialysis unit.
  
  
  METHODS
  Twenty men and one woman between the ages of 33 and 74 years with impaired renal function including ten patients with end-stage renal disease receiving maintenance hemodialysis.
  
  
  METHODS
  All patients received a single, oral, 200-mg dose of flecainide acetate followed by sequential venous blood sampling. Seven to 14 days after the single-dose study, each patient received 100 mg of flecainide acetate by mouth every 12 hours or every 24 hours for 10 days. Venous blood samples were drawn periodically during multiple dosing and sequentially after the last dose. Measurements and primary results: Peak flecainide acetate concentrations (micrograms/L) were 330 +/- 104 micrograms/L (mean +/- SD) after the single dose and 687 +/- 505 micrograms/L after multiple doses. Time to peak occurred at 3.3 +/- 2.3 hours and 2.7 +/- 1.2 hours after single and multiple doses, respectively. The apparent volume of distribution was 8.2 +/- 2.9 L/kg and 9.2 +/- 5 L/kg after single and multiple dose studies, respectively. Plasma elimination half-life after the single dose (20.4 +/- 9.0 hours) was significantly shorter (P less than .001) than after multiple doses (37.8 +/- 39.7 hours), as was total body clearance: 391 +/- 154 mL/min versus 302 +/- 194 mL/min. There were no statistically significant differences between pharmacokinetic measurements determined for patients on chronic hemodialysis when compared with nondialysis patients during the multiple-dose study.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Loma Linda University, California.
authors.forename: S C
authors.initials: SC
authors.lastname: Forland
authors.forename: R E
authors.initials: RE
authors.lastname: Cutler
authors.forename: R L
authors.initials: RL
authors.lastname: McQuinn
authors.forename: D C
authors.initials: DC
authors.lastname: Kvam
authors.forename: A M
authors.initials: AM
authors.lastname: Miller
authors.forename: G J
authors.initials: GJ
authors.lastname: Conard
authors.forename: S
authors.initials: S
authors.lastname: Parish
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005424:Flecainide / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism*; D008297:Male; D008875:Middle Aged
chemical_list: D005424:Flecainide